Medivir to present at the Erik Penser Bank Health Care Day

STOCKHOLM, Feb. 22, 2022 — Medivir AB (Nasdaq Stockholm: MVIR) today announces that its new CEO Jens Lindberg will participate at the Erik Penser Bank Health Care Day, Thursday February 24, 2022. Jens Lindberg took office at Medivir on January 24, 2022. He will present the company and its plan for the ongoing clinical study with fostroxacitabine bralpamide (formerly MIV-818).

About the company

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients.

Medivir is focusing on the development of fostroxacitabine bralpamide (MIV-818), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of It’s business model, and the drug development is conducted either by the company or in partnership.

Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. The companie share (ticker: MVIR) is listed on Nasdaq Stockholm’s Small Cap list.

Image Courtesy Medivir

This article was shared with Prittle Prattle News as a Press Release by PRNewswire

Related Posts

1 of 851